Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.13 Insider Own0.40% Shs Outstand79.88M Perf Week-1.59%
Market Cap7.01B Forward P/E- EPS next Y-4.47 Insider Trans7.65% Shs Float75.98M Perf Month3.03%
Income-486.10M PEG- EPS next Q-1.40 Inst Own73.90% Short Float6.04% Perf Quarter1.18%
Sales645.60M P/S10.86 EPS this Y26.80% Inst Trans-1.78% Short Ratio4.58 Perf Half Y5.25%
Book/sh5.88 P/B13.54 EPS next Y21.90% ROA-17.40% Target Price123.39 Perf Year-41.34%
Cash/sh18.16 P/C4.38 EPS next 5Y- ROE-86.40% 52W Range65.30 - 181.83 Perf YTD-53.30%
Dividend- P/FCF- EPS past 5Y-6.40% ROI-32.20% 52W High-56.21% Beta1.24
Dividend %- Quick Ratio5.10 Sales past 5Y236.40% Gross Margin86.40% 52W Low21.93% ATR2.94
Employees866 Current Ratio5.90 Sales Q/Q31.60% Oper. Margin-82.00% RSI (14)42.15 Volatility3.77% 3.77%
OptionableYes Debt/Eq2.33 EPS Q/Q75.90% Profit Margin-75.30% Rel Volume0.47 Prev Close80.98
ShortableYes LT Debt/Eq2.33 EarningsNov 03 AMC Payout- Avg Volume1.00M Price79.62
Recom2.10 SMA20-4.24% SMA50-7.27% SMA2000.37% Volume469,805 Change-1.68%
Nov-05-21Upgrade JP Morgan Neutral → Overweight $130
Sep-15-21Upgrade Guggenheim Neutral → Buy
Aug-05-21Upgrade JP Morgan Underweight → Neutral $92 → $87
Jun-15-21Initiated BTIG Research Buy $110
Apr-26-21Resumed Credit Suisse Neutral $72
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Jan-08-21Downgrade Raymond James Outperform → Mkt Perform
Jan-08-21Downgrade Morgan Stanley Overweight → Equal-Weight $95
Jan-08-21Downgrade JP Morgan Overweight → Underweight $96
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Nov-26-21 02:33PM  
08:46AM  
Nov-25-21 10:56AM  
Nov-23-21 11:08AM  
Nov-22-21 08:18PM  
11:23AM  
Nov-18-21 10:27AM  
Nov-17-21 10:07AM  
08:31AM  
08:30AM  
Nov-12-21 12:56PM  
10:53AM  
Nov-11-21 10:15AM  
Nov-10-21 09:54AM  
Nov-04-21 06:23PM  
10:08AM  
04:31AM  
Nov-03-21 05:25PM  
04:01PM  
Nov-02-21 04:30PM  
Oct-29-21 06:15PM  
Oct-27-21 08:30AM  
Oct-20-21 07:00AM  
Oct-19-21 09:25AM  
Oct-14-21 04:11PM  
Oct-13-21 09:15PM  
04:47PM  
06:26AM  
03:28AM  
Oct-12-21 06:40PM  
04:04PM  
04:04PM  
04:01PM  
10:37AM  
Oct-11-21 03:25PM  
09:13AM  
Oct-08-21 01:02PM  
Oct-07-21 12:14PM  
Oct-06-21 10:11AM  
Oct-05-21 11:33AM  
Oct-04-21 04:30PM  
07:00AM  
Sep-30-21 07:06PM  
Sep-27-21 08:30AM  
Sep-17-21 12:32PM  
Sep-14-21 08:30AM  
Sep-07-21 04:30PM  
08:30AM  
Sep-03-21 11:31AM  
Aug-31-21 05:57PM  
Aug-24-21 11:32AM  
Aug-05-21 09:23AM  
04:01AM  
Aug-04-21 05:55PM  
04:05PM  
08:30AM  
Jul-30-21 05:42PM  
Jul-28-21 03:03PM  
08:30AM  
Jul-19-21 10:44AM  
Jul-06-21 09:48AM  
Jun-30-21 06:41PM  
Jun-29-21 05:51AM  
Jun-21-21 07:00AM  
06:45AM  
Jun-04-21 11:31AM  
Jun-03-21 04:30PM  
May-28-21 06:55PM  
May-19-21 05:06PM  
08:37AM  
08:30AM  
May-18-21 09:18PM  
04:03PM  
12:53PM  
09:58AM  
08:50AM  
06:39AM  
May-17-21 04:05PM  
May-11-21 05:51AM  
May-07-21 12:57PM  
May-06-21 03:01AM  
May-05-21 07:15PM  
04:05PM  
02:45PM  
May-04-21 04:30PM  
May-03-21 01:22PM  
08:50AM  
08:02AM  
Apr-30-21 06:45PM  
04:05PM  
06:06AM  
Apr-28-21 12:34PM  
08:30AM  
Apr-26-21 04:05PM  
Apr-07-21 04:53PM  
Apr-01-21 10:39AM  
Mar-25-21 07:47AM  
Mar-23-21 08:30AM  
Mar-19-21 04:24PM  
Mar-18-21 04:31PM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGRAM DOUGLAS SPresident & CEONov 17Buy79.9425,0262,000,578365,082Nov 17 06:24 PM
BEHRENS M KATHLEENDirectorMar 10Option Exercise42.305,000211,500135,517Mar 10 08:04 PM
BEHRENS M KATHLEENDirectorMar 10Sale85.765,000428,800130,517Mar 10 08:04 PM
Wigzell Hans Lennart RudolfDirectorMar 08Option Exercise34.9210,000349,20026,518Mar 10 08:03 PM
Wigzell Hans Lennart RudolfDirectorMar 08Sale83.5110,000835,10016,518Mar 10 08:03 PM
Bratica JosephPrincipal Financial OfficerDec 11Option Exercise71.451,11579,6679,255Dec 14 08:00 PM
Bratica JosephPrincipal Financial OfficerDec 11Sale165.001,115183,9758,140Dec 14 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096705,710Dec 10 08:24 PM
Bratica JosephPrincipal Financial OfficerDec 08Option Exercise29.601,12533,3009,265Dec 10 08:23 PM
Bratica JosephPrincipal Financial OfficerDec 08Sale160.001,125180,0008,140Dec 10 08:23 PM